Basiliximab
Mechanism :
Basiliximab is a chimeric (murine/human) monoclonal antibody (IgG1k), produced by recombinant DNA technology, that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2Ra, also known as CD25 antigen) on the surface of activated T-lymphocytes.
Indication :
- Prophylaxis of acute organ rejection in patients receiving renal transplantation.
Contraindications :
Contraindicated in patients with known hypersensitivity to basiliximab or any other component of the formulation.
Dosing :
>35 kg:
20 mg IV within 2 hours before transplant, followed by 20 mg IV for 4 days following transplant (same as in adults);
<35 kg:
10 mg IV within 2 hours before transplant, followed by 10 mg IV for 4 days following transplant.
The second dose should be withheld if complications such as severe hypersensitivity reactions or graft loss occur.
Adverse Effect :
Constipation, nausea, abdominal pain, vomiting, diarrhea, dyspepsia, anaphylaxis, pain, peripheral edema, fever, hyperkalemia, hypokalemia, hyperglycemia, hypercholesterolemia, hypophosphatemia, hyperuricemia, dyspnea, acne, hypertension, headache, tremor, insomnia, anemia, infections.
Interaction :
The following medications have been administered concomitantly, with no increase in adverse reactions: ATG/ALG, Azathioprine, Corticosteroids, Cyclosporine, Mycophenolate Mofetil, And Muromonab-CD3.
Renal Dose :
Dose in Renal Impairment GFR (mL/min)
| 20-50 | Dose as in normal renal function |
| 10-20 | Dose as in normal renal function |
| <10 | Dose as in normal renal function |
Dose in Patients undergoing Renal Replacement Therapies
| CAPD | Not dialysed. Dose as in normal renal function |
| HD | Not dialysed. Dose as in normal renal function |
| HDF/High flux | Unknown dialysability. Dose as in normal renal function |
| CAV/VVHD | Not dialysed. Dose as in normal renal function |
Hepatic Dose :
No dosage adjustments are recommended.